相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors
Tao Jiang et al.
LUNG CANCER (2019)
Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB)
Fangping Ren et al.
ONCOTARGETS AND THERAPY (2019)
Astragalus polysaccharide (PG2) Ameliorates Cancer Symptom Clusters, as well as Improves Quality of Life in Patients with Metastatic Disease, through Modulation of the Inflammatory Cascade
Wen-Chien Huang et al.
CANCERS (2019)
Astragalus polysaccharides (PG2) Enhances the M1 Polarization of Macrophages, Functional Maturation of Dendritic Cells, and T Cell-Mediated Anticancer Immune Responses in Patients with Lung Cancer
Oluwaseun Adebayo Bamodu et al.
NUTRIENTS (2019)
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy
Mehmet A. Bilen et al.
CANCER (2019)
Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer
Rachel Howard et al.
SCIENTIFIC REPORTS (2019)
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients
Francesco Passiglia et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
Martin Reck
IMMUNOTHERAPY (2018)
Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
Aya Nakaya et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies
Dedong Cao et al.
ONCOIMMUNOLOGY (2018)
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
Koung Jin Suh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Stefan Diem et al.
LUNG CANCER (2017)
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
Stephen J. Bagley et al.
LUNG CANCER (2017)
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
P. F. Ferrucci et al.
BRITISH JOURNAL OF CANCER (2015)
Potential pathophysiological mechanism of cancer-related fatigue and current management
Chi-Tai Yeh et al.
FORMOSAN JOURNAL OF SURGERY (2014)
The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer
Graeme J. K. Guthrie et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Inhibitory Effect of Astragalus Polysaccharides on Lipopolysaccharide-Induced TNF-α and IL-1β Production in THP-1 Cells
Xiaojuan He et al.
MOLECULES (2012)
Fatigue during breast radiotherapy and its relationship to biological factors
C Wratten et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
分享论文
